Alberta reports second blood clot in Canada after AstraZeneca vaccine

0
12
AstraZeneca was a pioneer in the race to create an effective vaccine against COVID-19 since he started working with the University of Oxford.


|| []).push(function () { viAPItag.display(“vi_1088641796”) })

The overall frequency of VITT has been estimated to be approximately one in 100,000 to 250,000 doses

Content of the article

Alberta has confirmed a rare case of a blood clot in a patient who received the Oxford-AstraZeneca vaccine, the province’s chief medical officer of health said on Saturday.

Dr Deena Hinshaw said the male patient, who is in his 60s and recovering, marks the second Canadian case of a blood clot disorder known as vaccine-induced immune thrombotic thrombocytopenia, or VITT.

The case does not change the province’s risk assessment of the vaccine, she said.

“I continue to recommend AstraZeneca to anyone 55 years of age and over and recommend that all Albertans get vaccinated as soon as they can,” she said in a statement. “It is the best way to protect your health and that of those around you.”

To date, over 700,000 doses of AstraZeneca have been administered in Canada.

Content of the article

The worldwide frequency of VITT has been estimated to be about one in 100,000 to 250,000 doses, Hinshaw said.

In a striking comparison, she said Albertans 55 and older who are diagnosed with COVID-19 have a one in 200 chance of dying from the infection.

Extremely rare

A Quebecer was the first in Canada to develop a blood clot after being vaccinated with AstraZeneca.

The woman received the vaccine produced at the Serum Institute of India, known as Covishield, and was recovering at home, the Public Health Agency of Canada said on Tuesday.

“While every adverse reaction is unfortunate, it’s important to remember that these blood clots are extremely rare and this vaccine helps prevent the much higher risks that come from COVID-19 infection,” Hinshaw said.

|| []).push(function () { viAPItag.display(“vi_1088641796”) })

LEAVE A REPLY

Please enter your comment!
Please enter your name here